(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Pick Your Number one Sort Of Music- Bavarian leader questions Germany's Eurovision participation
- The World's Dazzling Regular Miracles
- The Best Internet Mastering Stages for Expertise Improvement
- Monetary Versatility: Get ready for Life's Unforeseen Difficulties
- Spain's Easter processions draw more tourists amid Iran war
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
- From blowouts to big interiors, ‘Tuscan Mom’ style is Gen Z’s answer to beige burnout
